



2014

## Palivizumab Administration Decreases Recurrent Wheeze

Shelly Daniels  
*University of North Dakota*

[How does access to this work benefit you? Let us know!](#)

Follow this and additional works at: <https://commons.und.edu/pas-grad-posters>



Part of the [Medical Immunology Commons](#), and the [Respiratory Tract Diseases Commons](#)

---

### Recommended Citation

Daniels, Shelly, "Palivizumab Administration Decreases Recurrent Wheeze" (2014). *Physician Assistant Scholarly Project Posters*. 114.

<https://commons.und.edu/pas-grad-posters/114>

This Poster is brought to you for free and open access by the Department of Physician Studies at UND Scholarly Commons. It has been accepted for inclusion in Physician Assistant Scholarly Project Posters by an authorized administrator of UND Scholarly Commons. For more information, please contact [und.common@library.und.edu](mailto:und.common@library.und.edu).

# Palivizumab Administration Decreases Recurrent Wheeze

Shelly Daniels

Physician Assistant Program, University of North Dakota School of Medicine & Health Sciences  
Grand Forks, ND 58012-9037 [www.med.und.nodak.edu](http://www.med.und.nodak.edu)

## Abstract

Children who have been infected with Respiratory Syncytial Virus have a higher incidence of wheeze-associated clinic visits and hospitalizations compared to children without previous RSV exposure. The purpose of this study is to determine if palivizumab, an immunoglobulin injection used to prevent RSV infections, can decrease the incidence of recurrent wheezing in children. The review of literature will follow male and female children from infancy to age 13 who were treated with palivizumab and compare these children to patients with similar demographics that were not treated with palivizumab to determine if there is any difference in incidence of wheezing. The anticipated results are that patients treated with palivizumab will have a decreased incidence of recurrent wheeze. The findings may indicate that prevention of RSV with palivizumab will improve long-term health in children.



## Introduction

Respiratory syncytial virus is a very common disorder seen in the pediatric population. RSV may lead to severe infections requiring admission to a pediatric intensive care unit, especially in children considered to be high-risk. Palivizumab is a humanized monoclonal antibody that was approved in the United States by the FDA in 1998 to prevent RSV infections. The purpose of this study is to determine if the incidence of recurrent wheezing can be decreased by preventing RSV infections with palivizumab.

## Statement of the Problem

Currently only high-risk patients are receiving palivizumab due to the high cost associated with the injections. It is unknown if administration of palivizumab would be beneficial for patients that are not considered to be high-risk. Studies are needed to determine if palivizumab administration can prevent recurrent wheezing and the healthcare costs associated with wheeze related clinic visits and hospital admissions.

## Research Question

- In patients treated with palivizumab, is there a statistical difference in recurrent wheeze when compared to children not given palivizumab?
- Are there long-term or even lifelong benefits to preventing RSV with palivizumab?

## Literature Review

- RSV is the single most common cause of bronchiolitis
- 30-40% of patients hospitalized with an RSV infection will wheeze later in childhood, and RSV infection in infancy may be an important precursor to asthma (Hay et al., 2012)
- RSV bronchiolitis may interfere with normal lung development or immune maturation and subsequently cause recurrent episodes of wheezing (Blanken et al., 2013)
- In a non-randomized, observational, prospective study conducted by Yoshihara et al. (2013) recurrent wheeze was reported in 18.9% of the untreated group and only 6.4% of the palivizumab treated group (RR, 0.34 [95% CI, 0.19-0.60] P < 0.001)
- When comparing a palivizumab treated group to a control group Simoes et al. (2007) determined the palivizumab treated group had a longer time to onset of recurrent wheeze (HR = 0.46, 95% CI = 0.29 to 0.74) and also a decrease in physician diagnosed recurrent wheeze (HR = 0.36, 95% CI = 0.25 to 0.83)
- In a study conducted by Blanken et al. in 2013, there was a significant difference in recurrent wheeze in the treated group (11.2%) versus the placebo group (20.9%) (See Table 1)
- Stein et al. (1999) determined through a longitudinal report that the risk of infrequent and frequent wheezing decreased enough to become non-significant by the age of thirteen
- Sigurs (2002) conducted a cohort study which determined that at age 7.5 years 23% of patients with RSV were diagnosed with asthma, whereas only 2% of the control patients were diagnosed with asthma (See Table 2)

## Discussion

- Palivizumab can decrease recurrent wheezing throughout childhood
- After correcting for variables such as daycare attendance, smoking in the home, furred pets in the home, number of people living in the home, etc., in patient groups, palivizumab groups were viewed to have a significant decrease in recurrent wheezing
- Reduction in recurrent wheeze remained statistically significant up to the age of thirteen
- Palivizumab administration can decrease clinic visits and hospital admissions during childhood and can improve quality of life

## Applicability to Clinical Practice

- Palivizumab has limited FDA approval in the U.S. and is limited to high-risk infants only
- Premature infants < 35wga or infants with chronic lung disease of prematurity should be offered palivizumab
- RSV prophylaxis with Synagis, palivizumab, is expensive and prior authorization for the antibody should be investigated prior to administration

## References

- Blanken, M. O., Rovers, M. M., Molenaar, J. M., Winkler-Seinstra, P., Meijer, A., Kimpen, J. L. L., & Bont, L. (2013). Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. *N Engl J Med*, 368(19), 1791-1799. doi:10.1056/NEJMoa1211917.
- Bocchini, Joseph A., et al. (2009). Policy statement - modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. *American Academy of Pediatrics*, 124(6), 1694-1695, 1696, 1697, 1698, 1699, 1700, 1701. doi:10.1542.
- Feltes, T. F., Cahalka, A. K., Meissner, H. C., Piazza, F. M., Carlin, D. A., Top Jr., F. H., . . . for the Cardiac Synagis Study Group. (2003). Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. *The Journal of Pediatrics*, 143(4), 532-540. doi:10.1016/j.jpeds.2007.02.032.
- Hay, W., Levin, M., Deterdig, R., Abzug, M., & Sondheimer, J. (2012). Respiratory syncytial virus disease. In A. Fried, & P. Boyle (Eds.), *Current diagnosis and treatment pediatrics* (21st Edition ed., pp. 1186-1187). United States: McGraw Hill.
- Kimpen, J. L. (2002). Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing. *Respiratory Research*, 3 Suppl 1, S40-5.
- McCance, K., Huether, S., Brashers, V., & Rote, N. (2010). Alterations of pulmonary function in children. In S. Clark, C. Crimmon Jones, C. Ketchum & B. Bagwill (Eds.), *Pathophysiology the biologic basis for disease in adults and children* (6th Edition ed., pp. 1326-1327). Maryland Heights, Missouri: Mosby Elsevier.
- Okayama, Y. (2013). Cellular and humoral immunity of virus-induced asthma. *Frontiers in Microbiology*, 4 doi:10.3389/fmicb.2013.00252.
- Paes, B., Mitchell, I. L. A., Harimoto, T., & Lancot, K. (2013). Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. *Clinical and Developmental Immunology*, 2013 doi:10.1155/2013/917068.
- Romero, J. (2003). Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: Results from four years of palivizumab usage. *Pediatric Infectious Disease Journal*, 22(2).
- Sigurs, N. (2002). A cohort of children hospitalised with acute RSV bronchiolitis: Impact on later respiratory disease. *Paediatric Respiratory Reviews*, 3(3), 177-183. doi:http://dx.doi.org.ezproxy.undmedlibrary.org/10.1016/S1526-0542(02)00191-4.
- Simoes, E. A., Grootuis, J. R., Carbonell-Estrany, X., Rieger, C. H., Mitchell, L. F., Fredrick, L. M., . . . Palivizumab Long-Term Respiratory Outcomes Study Group. (2007). Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. *The Journal of Pediatrics*, 151(1), 34-42. doi:10.1016/j.jpeds.2007.02.032.
- Stein, R. T. (2009). Long-term airway morbidity following viral LRTI in early infancy: Recurrent wheezing or asthma? *Paediatric Respiratory Reviews*, 10 Suppl 1, 29-31. doi:10.1016/S1526-0542(09)70013-2; 10.1016/S1526-0542(09)70013-2.
- Stein, R. T., Sherrill, D., Morgan, W. J., Holberg, C. J., Halonen, M., Taussig, L. M., . . . Martinez, F. D. (1999). Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. *The Lancet*, 354(9178), 541-545. doi:http://dx.doi.org.ezproxy.undmedlibrary.org/10.1016/S0140-6736(98)10321-5.
- Yoshihara, S., Kusuda, S., Mochizuki, H., Okada, K., Nishima, S., & Simoes, E. (2013). Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. *Pediatrics / American Academy of Pediatrics*, 132(5), 811. doi:10.1542/peds.2013-0982.

## Acknowledgements

- I would like to express heartfelt appreciation to Dr. Vikki McCleary who has served as the faculty advisor for this project.

Table 1. Days with Wheezing in the First Year of Life

Variable	Palivizumab (N=214)			Placebo (N=215)			RR	
	Total Log Days	Symptom Days	Incidence per Day	Total Log Days	Symptom Days	Incidence per Day	Absolute Reduction	95% CI
	no.	%		no.	%		symptom days	%
<b>Days with wheezing</b>								
First year of life	53,075	930	1.8	51,726	2,309	4.5	1,379	61 (56-65)
<2mo after prophylaxis	28,455	666	2.3	282,220	1,382	4.9	716	52 (46-59)
≥2mo after prophylaxis	24,620	264	1.1	23,506	927	3.9	663	73 (66-80)
During RSV season	26,176	646	2.5	26,081	1,348	5	702	52 (46-59)
Outside RSV season	26,899	284	1.1	25,645	961	3.7	677	73 (66-80)

The incidence of wheezing was calculated as the number of days with parent-reported airway symptoms divided by the number of log days during follow up. P < 0.001 for all comparisons except P = 0.006 for the category of less than 2 months after the end of prophylaxis. (Blanken et al. 2013)

Table 2. Number (percentage) of Children with Bronchial Obstructive Symptoms in the Respiratory Syncytial Virus Group and the Control Group at age 7.5

Symptoms	RSV Group (n=47)	Control Group (n=93)	P-Value	RR	95% CI
<b>Asthma</b>					
Cumulative	14/47 (30%)	3/93 (3%)	<0.0001	9.23	2.79-30.55
Current	11/47 (23%)	2/92 (2%)	<0.001	10.88	2.51-47.11
Current Atopic	7/47 (9%)	1/93 (1%)	0.002	13.85	1.76-109.30
<b>Recurrent Wheezing</b>					
Cumulative	13/47 (28%)	10/93 (11%)	0.015	2.57	1.22-5.42
Current	6/47 (13%)	0/93 (0%)	<0.001	Not Calculable	
<b>Any Wheezing</b>					
Cumulative	32/47 (68%)	32/93 (34%)	<0.001	1.98	1.40-2.79
Current	18/47 (38%)	2/93 (2%)	<0.0001	17.81	4.31-73.54

"Current symptoms" means disease during the preceding year; "Current, atopic asthma" means asthma with allergic sensitisation. (Sigurs et al., 2002).